ISRCTN15559229
Completed
未知
A study to evaluate efficacy and tolerability of partial enteral nutrition with exclusion diet and its effect on microbiome change in patients with mild to moderate ulcerative colitis: a quasi- experimental study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- lcerative colitis
- Sponsor
- All India Institute of Medical Sciences
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who are confirmed cases of mild to moderate ulcerative colitis
- •2\. Age: 18 – 70 years of either gender
- •3\. Patients on stable dose of mesalamine for past 4 weeks
- •4\. Patients on stable dose of azathioprine/6\-mercaptopurine for past 6 months
- •5\. Patients on stable doses of topical therapy for past 2 weeks
- •6\. Patients who are willing to participate
Exclusion Criteria
- •1\. Received oral steroids in the past 4 weeks
- •2\. Received oral antibiotics within past 2 weeks
- •3\. Patients with severe disease activity
- •4\. Patients with fulminant colitis requiring hospitalization
- •5\. Patients who have had surgery
- •6\. Patients with concomitant GI infection
- •7\. Patients with significant hepatic, renal, endocrine, respiratory, neurologic, or cardiovascular diseases will also be excluded
- •8\. Pregnant, lactating females
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
The study to evaluate the efficacy and safety of Polynucleotide on Acne ScarsAcne scarPolynucleotide, Acne scarTCTR20230213003SW HEALTHCARE CO.,LTD27
Recruiting
Phase 4
The study to evaluate the efficacy and safety of Polynucleotide for Facial Rejuvenation in ThailandHealthyPolynucleotide, Facial RejuvenationTCTR20230213002SW HEALTHCARE CO.,LTD25
Recruiting
Phase 4
The study to evaluate the efficacy and safety of Polynucleotide for Periorbital Rejuvenation in ThailandHealthyPolynucleotide, Periorbital RejuvenationTCTR20230214003SW HEALTHCARE CO.,LTD25
Completed
Phase 3
Study to evaluate the efficacy and tolerability of Pegfilgrastim in chemotherapy induced neutropeniaCTRI/2009/091/000579GENNOVA BIOPHARMACEUTICALS LTD
Completed
Phase 3
Study to evaluate the efficacy and tolerability of Filgrastim in chemotherapy induced neutropeniaCTRI/2009/091/000574GENNOVA BIOPHARMACEUTICALS LTD